Shareholder Alert: Ademi LLP investigates whether NGM Biopharmaceuticals, Inc. has obtained a Fair Price in its transaction with Atlas Neon

Provided By PR Newswire

Last update: Feb 26, 2024

MILWAUKEE, Feb. 26, 2024 /PRNewswire/ -- Ademi LLP is investigating NGM Bio (Nasdaq: NGM) for possible breaches of fiduciary duty and other violations of law in its transaction with Atlas Neon.